Product
SARS-CoV2-CTLS
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A Pilot Study of SARS-CoV-2 Specific Cytotoxic T Lymphocytes (SARS-CoV-2-CTLs) for Treatment of Mild to Moderate Coronavirus Disease 2019 (COVID-19)Status: Recruiting, Estimated PCD: 2024-12-31